Orthocell got a recommendation in the Age this morning under the article titled "Biotechs stall as risk appetite fades". Interesting read and shows how difficult a year it was in 2014 and considering that Orthocell ( given it was a 2014 start-up ) did well to be where it is now. Anyway 2014 is behind all the biotechs now and hopefully we can see the whole industry given the risk capital support that is seen amongst their global peers.
Retrace..., page-6
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
-0.005(1.16%) |
Mkt cap ! $89.07M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 43.0¢ | 42.0¢ | $90.9K | 214.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 12850 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 24056 | 2 |
View Market Depth
| Last trade - 15.54pm 27/09/2024 (20 minute delay) ? |
| OCC (ASX) Chart |